These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 33842191)

  • 21. Drug Repurposing Approach against Novel Coronavirus Disease (COVID-19) through Virtual Screening Targeting SARS-CoV-2 Main Protease.
    Chowdhury KH; Chowdhury MR; Mahmud S; Tareq AM; Hanif NB; Banu N; Reza ASMA; Emran TB; Simal-Gandara J
    Biology (Basel); 2020 Dec; 10(1):. PubMed ID: 33374717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
    Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
    J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2.
    Martin WR; Cheng F
    J Proteome Res; 2020 Nov; 19(11):4670-4677. PubMed ID: 32907334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.
    Chandra A; Gurjar V; Qamar I; Singh N
    J Biomol Struct Dyn; 2021 Aug; 39(12):4201-4211. PubMed ID: 32462970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an
    Elfiky AA
    J Biomol Struct Dyn; 2021 Jun; 39(9):3204-3212. PubMed ID: 32338164
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Gurung AB; Ali MA; Lee J; Abul Farah M; Al-Anazi KM
    Saudi J Biol Sci; 2020 Oct; 27(10):2674-2682. PubMed ID: 32837219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
    Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
    J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug repurposing using computational methods to identify therapeutic options for COVID-19.
    Mahdian S; Ebrahim-Habibi A; Zarrabi M
    J Diabetes Metab Disord; 2020 Dec; 19(2):691-699. PubMed ID: 32837954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular docking and simulation studies on SARS-CoV-2 M
    Lokhande KB; Doiphode S; Vyas R; Swamy KV
    J Biomol Struct Dyn; 2021 Nov; 39(18):7294-7305. PubMed ID: 32815481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2
    Singh S; Sk MF; Sonawane A; Kar P; Sadhukhan S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6249-6264. PubMed ID: 32720577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.
    Mslati H; Gentile F; Perez C; Cherkasov A
    J Chem Inf Model; 2021 Aug; 61(8):3771-3788. PubMed ID: 34313439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target.
    DurdaĞi S
    Turk J Biol; 2020; 44(3):185-191. PubMed ID: 32595355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors.
    Hamed M; El-Hasab M; Mansour FR
    Virusdisease; 2021 Jun; 32(2):279-285. PubMed ID: 33948452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNA as an off-target for FDA-approved drugs.
    Fullenkamp CR; Schneekloth JS
    Nat Chem; 2023 Oct; 15(10):1329-1331. PubMed ID: 37697037
    [No Abstract]   [Full Text] [Related]  

  • 36. Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer's, and diabetes.
    Malar DS; Verma K; Prasanth MI; Tencomnao T; Brimson JM
    Sci Rep; 2024 Feb; 14(1):4328. PubMed ID: 38383841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives.
    Ghosh A; Kar PK; Gautam A; Gupta R; Singh R; Chakravarti R; Ravichandiran V; Ghosh Dastidar S; Ghosh D; Roy S
    RSC Med Chem; 2022 Jun; 13(6):647-675. PubMed ID: 35814927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for inhibitors against SARS-CoV-2 and its variants.
    Yuan W; Dong X; Chen L; Lei X; Zhou Z; Guo L; Wang J
    Biosaf Health; 2022 Jun; 4(3):186-192. PubMed ID: 35574239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease.
    Oktay L; Erdemoğlu E; Tolu İ; Yumak Y; Özcan A; Acar E; Büyükkiliç Ş; Olkan A; Durdaği S
    Turk J Biol; 2021; 45(4):459-468. PubMed ID: 34803447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.
    Singh R; Gautam A; Chandel S; Sharma V; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
    In Silico Pharmacol; 2021; 9(1):27. PubMed ID: 33842191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.